Nivolumab Boosted Survival in Relapsed Mesothelioma

KEYNOTE-598: Dual PD-1 and CTLA-4 Checkpoint Blockade Confers No Therapeutic Benefit Beyond PD-1 Blockade Alone in PD-L1–Positive NSCLC

LCMC3 Findings Indicate Neoadjuvant Atezolizumab Safe, Efficacious in Resectable Stage IB-IIIB NSCLC

Genetically Tailored Treatment Approach Did Not Improve Survival in Stage II-III NSCLC

Can We Use the Word ‘Cure’ for a Subset of Selected Patients With Advanced NSCLC?

Immune Checkpoint Inhibitors Have Led to Substantial Improvements in Lung Cancer but Are Still Not a ‘Cure’

Acute Admissions Rates for Lung Cancer Patients Up During Pandemic, Not Linked to COVID-19

Modeling Analyses Show That Expansions in Lung Cancer Screening Guidelines to Better Capture Underrepresented Populations Still Need Work

Young Investigators Awarded Grants to Study COVID-19 and Lung Cancer

Lung Ambition Alliance: Stronger Together 

Use of Predictive Biomarkers, Incorporating Chemotherapy—What Is Best When Using Immunotherapy in Advanced NSCLC?

Patient Advocate Comment: Amivantamab for Exon 20